Page 10 - Boxed Warning News Today

ZILBRYSQ® is now commercially available by prescription in the United States and dispensed by UCBs selected exclusive specialty pharmacy PANTHERx® Rare Pharmacy.ZILBRYSQ is FDA-approved as the...

Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PTWALTHAM, Mass., Jan. 03, 2024 -- Ardelyx, Inc. , a biopharmaceutical company founded with a mission to discover, develop and...

The FDA has approved Welireg (belzutifan) for the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet

Jylamvo, an FDA-approved oral solution formulation of methotrexate, is now available from Shorla Oncology and Eversana.

Jylamvo, an oral solution formulation of methotrexate, is now available from Shorla Oncology and Eversana.

Jylamvo, an FDA-approved oral solution formulation of methotrexate, is now available from Shorla Oncology and Eversana.

Tardive dyskinesia (TD) is an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents (DRBAs) that can range in severity and presentation and can impact social, emotional, and functional components of daily life. There are treatments that can effectively manage TD, but first it needs to be recognized and accurately diagnosed.

The FDA has approved Alyglo (immune globulin intravenous, human-stwk) 10% liquid to treat primary humoral immunodeficiency in adults.

(BPT) - Moira manages her depression and tardive dyskinesia and is supported by her husband and care partner Forrest.